Tarix Orphan obtains FDA fast track status for TXA127 to treat DMD
The approval has been granted for TXA127 to reduce skeletal muscle damage and fibrosis, allowing to improve muscle strength in DMD patients. DMD is a genetic disorder that
Novartis has signed a research partnership and licensing agreement with Unnatural Products (UNP) valued at up to $1.7bn to develop macrocyclic peptide therapeutics targeting cardiovascular diseases.
The FDA has determined MPI’s Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL (1.25 g/5 mL vials) to be bioequivalent and, therefore, therapeutically equivalent to Delalutin Injection, 250 mg/mL
The trial is a randomized, double blind, active control, multi-center, global study in patients with chronic plaque psoriasis to compare the safety, efficacy and immunogenicity of M923 with
OTO-311 is a sustained-exposure formulation of potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. The approval has been granted to commence a Phase I dose escalation clinical safety